Download presentation
Presentation is loading. Please wait.
Published bySherman Davidson Modified over 9 years ago
2
Approach To Abdominal Pain Dr. Nahla A Azzam MRCP,FACP Assistant Professor &Consultant Gastroenterology
3
One of the most common causes for OP & ER visits Multiple abd and non-abd pathologies can cause abd pain, therefore an organized approach is essential Some pathologies require immediate attention Abdominal pain
4
Introduction Abdominal pain is an unpleasant experience commonly associated with tissue injury. The sensation of pain represents an interplay of pathophysiologic and psychosocial factors.
5
ANATOMIC BASIS OF PAIN Sensory neuroreceptors in abdominal organs are located within the mucosa and muscularis of hollow viscera, on serosal structures such as the peritoneum, and within the mesentery..
6
two distinct types of afferent nerve fibers: myelinated A-delta fibers and unmyelinated C fibers. A-delta fibers are distributed principally to skin and muscle and mediate the sharp, sudden, well-localized pain that follows an acute injury.
7
C fibers are found in muscle, periosteum, mesentery, peritoneum, and viscera. Most nociception from abdominal viscera is conveyed by this type of fiber and tends to be dull, burning, poorly localized
8
The abdominal pain receptors are directly activated by substances released in response to: local mechanical injury Inflammation Tissue ischemia and necrosis Thermal or radiation injury.
10
Definitions Acute abdominal pain with recent onset within hours-days Chronic abdominal pain is intermittent or continuous abdominal pain or discomfort for longer than 3 to 6 months. Abdominal Pain
11
Acute abdominal pain Surgical –Appendicitis –Cholecystitis –Bowel obstruction –Acute mesenteric ischemia –Perforation –Trauma –Peritonitis Medical –Cholangitis –Pancreatitis –Choledocholithiasis –Diverticulitis –PUD –Gastroenteritis –Nonabdominal causes Abdominal Pain
12
Onset Character Location Severity Duration Abdominal Pain History
13
Eating Drinking Drugs Body position Defecation Abdominal Pain History Aggravating and alleviating factors
14
Anorexia Weight loss Nausea/vomiting Bloating Constipation Diarrhea Hemorrhage Jaundice Dysurea Menstruation Abdominal Pain History Associated symptoms
15
PMH: Similar episodes in past Other relevant medical problems Systemic illnesses such as scleroderma, lupus, nephrotic syndrome, porphyrias, and sickle cell disease often have abdominal pain as a manifestation of their illness. PSH: Adhesions, hernias, tumors, trauma Drugs: ASA, NSAIDS, antisecretory, antibiotics, etc GYN: LMP, bleeding, discharge Social: Nicotin, ethanol, drugs, stress Family: IBD, cancer, ect Abdominal Pain History
16
Physical Exam Abdominal Pain General appearance Ambulant Healthy or sick In pain or discomfort Stigmata of CLD Vital signs
17
Physical Exam- Abdomen Abdominal Pain Inspection Distention, scars, bruises, hernia Palpation Tenderness Guarding Rebound Masses Auscultation Abd sounds: present, hyper, or absent
18
CBC Liver profile Amylase Glucose Urine dipsticks Pregnancy test Laboratory Testing Abdominal Pain
19
Plain films Ultrasonography Computed Tomography Imaging Abdominal Pain
20
Endoscopy EGD Colonoscopy ERCP/EUS Abdominal Pain
21
Approach Abdominal pain Acute Chronic Surgical nonsurgical Abdominal Pain
22
RUQ-PAIN Cholecystitis Cholangitis Hepatitis RLL pneumonia Subdiaphragmatic abscess Abdominal Pain
23
LUQ- PAIN Splenic infarct Splenic abscess Gastritis/PUD Abdominal Pain
24
RLQ-PAIN Appendicitis Inguinal hernia Nephrolithiasis IBD Salpingitis Ectopic pregnancy Ovarian pathology Abdominal Pain
25
LLQ-PAIN Diverticulitis Inguinal hernia Nephrolithiasis IBD Salpingitis Ectopic pregnancy Ovarian pathology Abdominal Pain
26
Epigastric-Pain PUD Gastritis GERD Pancreatitis Cardiac (MI, pericarditis, etc) Abdominal Pain
27
Periumbelical-Pain Pancreatitis Obstruction Early appendicitis Small bowel pathology Gastroenteritis Abdominal Pain
28
Pelvic-Pain UTI Prostatitis Bladder outlet obstruction PID Uterine pathology Abdominal Pain
29
Diffuse Pain Gastroenteritis Ischemia Obstruction DKA IBS Others –FMF –AIP –Vitamin D deficiency –Adrenal insufficiency Abdominal Pain
30
Chronic abd pain approach History Intermittentcontinuous biliary intest. obstruction Intst. angina endometriosis porphoryea IBS metastasis Intest. tumor pancreatic disorder pelvic inflammation Addison dis functional disorder Alarm symptoms IDA Hematochezia Endoscopy Cholestasis US/CT ERCP Fever C&S CT Weight loss Endoscopy CT Abdominal Pain
31
Take Home Points Good history and physical exam is important ( History is the most important step of the diagnostic approach ) Lab studies limitations. Imaging studies selection (appropriate for presentation and location). Alarm symptoms oriented investigations Early referral of sick patients Treatment initiation Abdominal Pain
32
Irritable bowel syndrome (IBS) is an intestinal disorder that causes abdominal pain or discomfort, cramping or bloating, and diarrhea or constipation. Irritable bowel syndrome is a long-term but manageable condition. What Is IBS
33
First described in 1771. 50% of patients present <35 years old. 70% of sufferers are symptom free after 5 years. GPs will diagnose one new case per week. GPs will see 4-5 patients a week with IBS. 32 Introduction
34
It is estimated that between 10% and 15% of the population of North America, or approximately 45 million people, have irritable bowel syndrome. only about 30% of them will consult a doctor about their symptoms. IBS tends to be more common in In women, IBS is 2 to 3 times more common than in men. Who Gets IBS?
35
Rome III Diagnostic criteria. Manning’s Criteria. 34 Diagnostic Criteria
36
The positive predictive value (PPV) of the Manning criteria for the diagnosis of IBS has ranged between 65 and 75%, 35
37
At least 12 weeks history, which need not be consecutive in the last 12 months of abdominal discomfort or pain that has 2 or more of the following: –Relieved by defecation. –Onset associated with change in stool frequency. –Onset associated with change in form of the stool. 36 Rome III Diagnostic Criteria.
38
Supportive symptoms. –Constipation predominant: one or more of: BM less than 3 times a week. Hard or lumpy stools. Straining during a bowel movement. –Diarrhoea predominant: one or more of: More than 3 bowel movements per day. Loose [mushy] or watery stools. Urgency. 37 Rome IlI Diagnostic Criteria.
39
–General: Feeling of incomplete evacuation. Passing mucus per rectum. Abdominal fullness, bloating or swelling. 38 Rome IlI Diagnostic Criteria.
40
Diarrhoea predominant. Constipation predominant. Pain predominant. 39 Subtypes
41
In people with IBS in hospital OPD. –25% have depression. –25% have anxiety. Patients with IBS symptoms who do not consult doctors [population surveys] have identical psychological health to general population. In one study30 % of women IBS sufferers have fibromyalgia 40 Associated Symptoms
42
IBS Pathophysiology Heredity; nature vs nurture Dysmotility, “ spasm ” Visceral Hypersensitivity Altered CNS perception of visceral events Psychopathology Infection/Inflammation Altered Gut Flora
43
Immune Activation Mast Cell Activation Luminal Flora A New Paradigm
44
Immune Activation Mast Cell Activation Luminal Flora STRESS INFECTION ALTERED MICROBIOTA
45
Immune Activation Mast Cell Activation Luminal Flora
46
Systemic Immune Compartment in IBS Serum Cytokines Dinan, et al. Gastroenterology. 2006. * IL-6 IBSControls 65432106543210 IL-6 (pg/ml) * sIL-6r IBSControls 0 50000 100000 150000 sIL-6r
47
Mucosal Compartment Frank inflammation Immune Activation – ↑ IEL’s – ↑ CD3 +, CD25 + Chadwick et al, 2002 Decreased IgA+ B Cells Forshammar et al, 2008 Altered expression of genes involved in mucosal immunity Aerssens et al, 2008
48
10-14% incidence following confirmed bacterial gastroenteritis Dunlop, et al. 2003. Mearin, et al. 2005. Risk factors –Female –Severe illness –Pre-morbid psyche Depression –Persistent inflammation EC cells T lymphocytes Post-Infectious IBS Dunlop, et al. 2003. 300 200 100 0 PI-IBS Patient Controls Volunteers Lamina Propria T Lymphocytes Per hpf ** 75 50 25 0 PI-IBS Patient Controls Volunteers EC Cells Per hpf **
49
Lessons from PI-IBS Disturbed Flora Susceptible Host Inflammatory Response Myo-Neural Dysfunction SYMPTOMS
50
Inflammatory bowel disease. Cancer. Diverticulosis. Endometriosis. Celiac disease 49 Differential Diagnosis
51
50
52
Blood test for IBS Current best evidence does not support the routine use of blood tests to exclude organic gastrointestinal disease in patients who present with typical IBS symptoms without alarm symptoms.
53
Reasons to Refer Age > 45 years at onset. Family history of bowel cancer. Failure of primary care management. Uncertainty of diagnosis. Abnormality on examination or investigation. 52
54
Urgent Referral Constant abdominal pain. Constant diarrhoea. Constant distension. Rectal bleeding. Weight loss or malaise. 53
55
Treatment Patients’ concerns. Explanation. Treatment approaches. 54
56
Usually very concerned about a serious cause for their symptoms. Take time to explore the patients agenda. Remember that investigations may heighten anxiety. 55 Patients’ Concerns.
57
Placebo effect of up to 70% in all IBS treatments. Treatment should depend on symptom sub-type. Often considerable overlap between sub-groups. 56 Treatment Approaches.
58
Antispasmodics will help 66%. Mebeverine is probably first choice. Hyoscine 10mg qid can be added. 57 Pain Predominant.
59
Smooth Muscle Relaxants Some patients improve particularly those whose symptoms are induced by meals Most studies that have looked at these medications have been poorly designed, poorly controlled, and have not shown significant benefits above placebo
60
A data from meta-analysis of 22 studies involving 1778 patients and 12 different antispasmodic agents demonstrated modest improvements in global IBS symptoms and abdominal pain However, up to 68% of patients suffered side effects when given the high dose required to improve abdominal pain Page and Dirnberger, 1981
61
Poor evidence for efficacy. Better evidence for tricyclics and SSRIs. 60 Antidepressants
62
Tricyclic Antidepressants TCAs likely modulate pain both centrally and peripherally The best data supporting the use of TCAs in the treatment of IBS is from a large placebo-controlled study evaluating desipramine. This highlights the fact that if a patient can tolerate some of the side effects of a TCA, then he or she is more likely to note an improvement in chronic abdominal pain compared with a patient treated with placebo [Drossman et al. 2003]
63
Selective Serotonin Reuptake Inhibitors (SSRIs Six studies have been conducted to date, two each involving fluoxetine, paroxetine and citalopram Talley et al. 2008; Tack et al. 2006; Vahedi et al. 2005; Tabas et al. 2004; Kuiken et al. 2003; Masand et al. 2002]. Most patients noted an improvement in overall wellbeing, although none of the studies showed any benefit with regards to bowel habits, and abdominal pain was generally not improved
64
Only one trial has provided a head-to-head comparison between a TCA (imipramine 50 mg) and an SSRI (citalopram 40 mg), Although neither drug demonstrated significant improvements in global IBS symptoms over placebo Talley et al. 2008
65
Constipation Lifestyle Modifications Bowel Training and Education Fibre Twelve randomized controlled trials have been performed to date evaluating the efficacy of fiber in the treatment of IBS. Four of these studies noted an improvement in stool frequency (polycarbophil and ispaghula husk), while one noted an improvement in stool evacuation Toskes et al. 1993; Jalihal and Kurian, 1990; Prior and Whorwell, 1987; Longstreth et al. 1981]. No improvement in abdominal pain 30-50% of patients treated with a fiber product will have a significant increase in gas
66
Over-the-counter Medications PEG Lactulose Tegaserod stimulate gastrointestinal peristalsis, increase intestinal fluid secretion and reduce visceral sensation 5 HT agonist FDA approved for chronic constipation in women.
67
Lubiprostone stimulates type 2 chloride channels in epithelial cells of the gastrointestinal tract thereby causing an efflux of chloride into the intestinal lumen It was approved by the FDA for the treatment of adult men and women with chronic constipation in January 2006 Nausia and diarrhea 6-8%
68
Increasing dietary fibre is sensible advice. Fibre varies, 55% of patients will get worse with bran. “Medical fibre” adds to placebo effect. Loperamide may help Diarrhea predominant 67
69
Diarrhea Loperamide inhibiting intestinal secretion and peristalsis, loperamide slows intestinal transit and allows for increased fluid reabsorption, thus improving symptoms of diarrhea
70
Alosetron is 5-HT3 receptor antagonist that slows colonic transit meta-analysis of eight randomized controlled trials involving 4842 patients determined that alosetron provided a significant reduction in the global symptoms of diarrhea, abdominal pain, and bloating in patients with IBS and diarrhea four-fold increased risk for ischemic colitis compared to placebo [Ford et al. 2008
71
RECENT THERAPY Antibiotics PROBIOTICS
72
“Target” Trials 1,260 patients with non-constipation irritable bowel syndrome (IBS) recruited in the US and Canada Rifaximin 550 mg, 3 times daily, for 2 weeks Primary endpoint: –The proportion of subjects who achieved adequate relief of IBS symptoms for at least 2 weeks during the first 4 weeks (weeks 3-6) of the 10-week follow-up phase Also assessed relief of IBS bloating and symptom responses at 12 weeks (10 weeks after end of therapy)
73
EndpointsTarget 1 Rif vs Placebo Target 2 Rif vs Placebo Combined Rif vs Placebo Adequate relief of IBS symptoms 41% vs 31%41% vs 32% Adequate relief of IBS bloating 40% vs 29%41% vs 32%40% vs 30% All p<0.03 Hitting the Target!
74
Probiotics
75
Mode of Action of Probiotics? Competition with, and exclusion, of pathogens Anti-bacterial: –Produce bacteriocins –Destroy toxins Enhance barrier function, motility Enhance host immunity –Immune modulation –Cytokine modulation –IgA production Metabolic functions
76
% Answering “Yes” at Week 4 70 60 50 40 30 80 B. infantis 1x10 6 B. infantis 1X10 10 B. infantis 1X10 8 Placebo P=0.0118 Global Assessment of Symptom Relief
77
Prospective, multicenter, double-blind, placebo- controlled, crossover trial assessing the efficacy and safety of the probiotic, VSL#3 Patients treated with VSL#3 had a significant improvement in the primary endpoint, which was the global relief of IBS symptoms (p < 0.05). Secondary endpoints of abdominal pain (p = 0.05) and bloating (p < 0.001) were also improved. Guandalini et al. 2008
78
Avoid caffeine. Limit your intake of fatty foods. Fats increase gut sensations, which can make abdominal pain seem worse. If diarrhea is your main symptom, limit dairy products, fruit, or the artificial sweetener sorbitol. Increasing fiber in your diet may help relieve constipation. Avoiding foods such as beans, cabbage, or uncooked cauliflower or broccoli can help relieve bloating or gas. What about diet?
79
Hypnosis. Hypnosis can help some people relax, which may relieve abdominal pain. Relaxation or meditation. Relaxation training and meditation may be helpful in reducing generalized muscle tension and abdominal pain. Biofeedback. Biofeedback training may help relieve pain from intestinal spasms. It also may help improve bowel movement control in people who have severe diarrhea. Alternative Medicine
80
Self-help IBS network, IBS support group Awareness 79
81
THANK YOU 80
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.